Drug profile · INN
bismuth subsalicylate
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE
bismuth subsalicylate (BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — bismuth subsalicylate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
bismuth subsalicylate (BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Cyclooxygenase inhibitor
Primary target: Cyclooxygenase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is bismuth subsalicylate?
bismuth subsalicylate (BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE) is a cyclooxygenase inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for bismuth subsalicylate?
BISMUTH SUBSALICYLATE, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE is a marketed brand name for bismuth subsalicylate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of bismuth subsalicylate?
bismuth subsalicylate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.